3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Withdrawn
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
CNS
1
Conditions
Breast Neoplasms
34
HER2-positive Breast Cancer
5
Neoplasms
4
Brain Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Meningeal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
Central Nervous System Diseases
1
Breast Diseases
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage IA Breast Cancer AJCC v8
1
Interventions
Paclitaxel
50
Capecitabine
50
Trastuzumab
38
Fulvestrant
31
pembrolizumab
27
Cyclophosphamide
27
Carboplatin
27
Gemcitabine
23
Letrozole
21
palbociclib
19
Docetaxel
19
Lapatinib
18
Bevacizumab
18
exemestane
17
eribulin
15
Everolimus
14
abemaciclib
13
Vinorelbine
13
Nivolumab
13
Magnetic Resonance Spectroscopy
12
Cisplatin
12
Anastrozole
12
trastuzumab deruxtecan
11
Zoledronic Acid
11
Doxorubicin
11
Albumin-Bound Paclitaxel
11
olaparib
10
Tamoxifen
10
Specimen Handling
10
Radiotherapy
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
tucatinib
×
Breast
×
Clear all
NCT07193394
2026-02-23
H3RAKLES
Institut Curie
Phase 2
Recruiting
20 enrolled
NCT05868226
2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1
Recruiting
124 enrolled
NCT04896320
2023-06-22
2019-101826
Providence Health & Services
Phase 1/2
Withdrawn